Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on combating ototoxicity (hearing loss) in cancer patients receiving cisplatin-based chemotherapy. The company's sole commercial product, PEDMARK® (sodium thiosulfate injection), is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients aged 1 month and older with localized, non-metastatic solid tumors. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 under the brand name PEDMARQSI®. The company commercializes PEDMARK directly in the United States and has an exclusive licensing agreement with Norgine Pharmaceuticals for commercialization in Europe, the U.K., Australia, and New Zealand. Fennec is actively expanding PEDMARK's clinical evidence base through institution-led studies across additional tumor types and patient populations, including adolescent and young adult (AYA) patients and adults with head and neck cancers. The company is also pursuing registration in Japan following positive Phase 2/3 clinical trial results. PEDMARK has Orphan Drug Exclusivity in the U.S. and patent protection extending until 2039. Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with platinum-based chemotherapy, with 60-90% of cisplatin-treated patients potentially developing hearing loss. Fennec trades on NASDAQ under the ticker FENC and on the TSX under FRX. Updated Mar 24, 2026